Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has a beta value of 1.07 and has seen 1.06 million shares traded in the last trading session. The company, currently valued at $577.35M, closed the last trade at $9.23 per share which meant it gained $0.21 on the day or 2.33% during that session. The CRVS stock price is -1.52% off its 52-week high price of $9.37 and 86.67% above the 52-week low of $1.23. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.14 million shares traded. The 3-month trading volume is 605.29K shares.
The consensus among analysts is that Corvus Pharmaceuticals Inc (CRVS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Sporting 2.33% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CRVS stock price touched $9.23 or saw a rise of 2.22%. Year-to-date, Corvus Pharmaceuticals Inc shares have moved 424.43%, while the 5-day performance has seen it change 3.82%. Over the past 30 days, the shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have changed 66.01%. Short interest in the company has seen 2.44 million shares shorted with days to cover at 4.73.
Wall Street analysts have a consensus price target for the stock at $9.5, which means that the shares’ value could jump 2.84% from current levels. The projected low price target is $7.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -30.01% off the targeted high while a plunge would see the stock lose 24.16% from current levels.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
Figures show that Corvus Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 449.40% over the past 6 months, with this year growth rate of 19.64%, compared to 17.30% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.89% over the past 5 years.
CRVS Dividends
Corvus Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
Insiders own 4.02% of the company shares, while shares held by institutions stand at 44.26% with a share float percentage of 46.11%. Investors are also buoyed by the number of investors in a company, with Corvus Pharmaceuticals Inc having a total of 56.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 6.94 million shares worth more than $12.64 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 14.1596% of shares outstanding.
The other major institutional holder is SAMLYN CAPITAL, LLC, with the holding of over 6.12 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.14 million and represent 12.4861% of shares outstanding.
